In AXL-high-expressing EGFR-mutated lung cancer cells, osimertinib exposure inhibits ERK phosphorylation and thereby decreases the expression of SPRY4 maintained by ERK-mediated MAPK signal12,28,29. Here, SPRY4 is linked to lung carcinoma.